Coherus Oncology, Inc.CHRSNASDAQ
LOADING
|||
PB Ratio: Premium Valuation
Trending higher, above historical average, structural decline.
Left:
||||
Price-to-book ratio
Latest
-1.20
↑ 71% above average
Average (9y)
-4.06
Historical baseline
Range
High:60.96
Low:-123.01
CAGR
-40.2%
Structural decline
| Period | Value | Change |
|---|---|---|
| 2024 | -1.20 | +26.1% |
| 2023 | -1.62 | +63.8% |
| 2022 | -4.47 | -136.3% |
| 2021 | 12.32 | +179.0% |
| 2020 | 4.42 | -63.0% |
| 2019 | 11.92 | +178.2% |
| 2018 | -15.25 | -199.6% |
| 2017 | 15.31 | -74.9% |
| 2016 | 60.96 | +149.6% |
| 2015 | -123.01 | - |